BusinessAgile Therapeutics Receives Approximately $3 Million in Non-Dilutive Funding from New Jersey’s Technology Business Tax Certificate Transfer ProgramBy Nasdaq OMXDec 1, 2016, 1:00 PM UTC
BusinessAgile Therapeutics Reports Third Quarter 2016 Financial Results and Announces Completion of Subject Visits for Twirla® Phase 3 SECURE Clinical TrialBy Nasdaq OMXNov 7, 2016, 9:10 PM UTC
BusinessAgile Therapeutics to Present at the 28th Annual ROTH ConferenceBy Nasdaq OMXMar 3, 2016, 9:15 PM UTC
BusinessAgile Therapeutics, Inc. Announces Full Exercise of Option to Purchase Additional Shares by UnderwritersBy Nasdaq OMXFeb 4, 2016, 9:10 PM UTC
BusinessAgile Therapeutics Announces Pricing of Its Public Offering of Common StockBy Nasdaq OMXJan 22, 2016, 2:17 PM UTC
BusinessAgile Therapeutics to Present at Noble Financial Capital Markets’ Twelfth Annual Equity ConferenceBy Nasdaq OMXJan 15, 2016, 9:32 PM UTC
BusinessAgile Therapeutics Receives Approximately $6 Million in Non-Dilutive Funding From New Jersey’s Technology Business Tax Certificate Transfer ProgramBy Nasdaq OMXDec 1, 2015, 12:45 PM UTC
